Indications
Sacubitril + Valsartan tablet is used to lower the risk of cardiovascular death and of hospital admission for heart failure in patients with chronic heart failure (NYHA Class II to IV) and reduced ejection fraction. It is also used to treat symptomatic heart failure with systemic left ventricular systolic dysfunction in children aged one year and older. Doctors usually give Sacubitril + Valsartan along with other heart failure treatments, and it takes the place of an angiotensin-converting enzyme inhibitor (ACEi) or another ARB.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Sacubitril + Valsartan is a tablet that combines two drugs: sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin receptor blocker. Sacubitril is a prodrug. Its active metabolite, LBQ657, inhibits neprilysin (neutral endopeptidase; NEP), while valsartan blocks the angiotensin II type-1 (AT1) receptor.
In patients with heart failure, the cardiovascular and renal effects of Sacubitril + Valsartan come from two actions working together. LBQ657 raises the levels of peptides that neprilysin normally breaks down, such as natriuretic peptides. At the same time, valsartan stops angiotensin II from having its effects. It does this by selectively blocking the AT1 receptor, and it also inhibits angiotensin II-dependent aldosterone release.
Pregnancy & Breastfeeding
Pediatric use: Safety and effectiveness haven't been established in children under 1 year of age.
Geriatric use: Researchers saw no relevant pharmacokinetic differences in elderly patients (over 65 years) or very elderly patients (over 75 years) when compared with the overall population.
Hepatic impairment: No dose adjustment is needed when this tablet is given to patients with mild hepatic impairment (Child-Pugh A classification). It isn't recommended in severe hepatic impairment, because no studies have been done in these patients.
Renal impairment: No dose adjustment is needed in mild renal impairment (eGFR 60 to 90 ml/min/1.73 m2) or moderate renal impairment (eGFR 30 to 60 ml/min/1.73 m2). In severe renal impairment (eGFR <30 ml/min/1.73 m2), the recommended starting dose is 24/26 mg twice daily.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.